Background: This study was conducted to assess the effi cacy of OM-85 BV (Broncho-Vaxom) in the prevention of pediatric recurrent respiratory tract infections (RTIs). Available evidence suggests that defi ning recurrent RTIs as ≥3 infections per fall-winter semester is both medically and epidemiologically justifi ed. Therefore, this criterion was chosen as a primary endpoint.
Introduction
O M-85 BV (Broncho-Vaxom) is an immunostimulant medication used to prevent recurrent respiratory tract infections (RTIs). The mechanism of its action has recently been reviewed by Rozy et al. [1] OM-85 BV has been shown to induce the terminal maturation of human dendritic cells, with an enhanced T cell-stimulatory capacity in vitro. [2] The broncho-alveolar lavage of adults treated with OM-85 BV [3, 4] showed an increase in the helper/suppressor T lymphocyte ratio, a stimulation of the impaired alveolar macrophage activity, and increased concentrations of interferon-γ.
The clinical aspects of recurrent pediatric RTIs have been dealt with in detail in a recent systematic review, [5] including pathogenesis, prevention and "key" trials with OM-85 BV. Therefore, the paper presented herein shall concentrate on a meta-analytic approach, attempting to quantify the effectiveness of OM-85 in the secondary prevention of recurrent RTIs in children.
It is widely accepted that recurrent RTIs in childhood represent a problem per se in addition to increasing predisposition to future respiratory problems. Repeated lower RTIs in the fi rst 3 years of life show a positive association with wheezing up to the age of 7 years. [6] However, the concept of recurrence in relation with RTIs presents some problems since there is no generally agreed defi nition. Preschool children may contract between four and six RTIs over the course of a year without this representing a true deviation from "normality". [7] In a German study it was shown [8] that the number of febrile episodes in the fi rst year of life was superior to three in about 28% of the infants and that about 9% had two or more courses of antibiotics. Several episodes seem "normal" since several peaks of exposure to different agents occur during each season. [9] Some authors [10] OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review
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have attempted to defi ne recurrence of infection by clinical presentation, e.g., three episodes of otitis over 6 months or two episodes of sinusitis and/or recurrent bronchopneumonia in 6 months or four episodes of rhinopharyngitis in 6 months. Such a classifi cation, particularly in younger children, however seems somewhat artifi cial. Therefore, epidemiological and clinical observations favor the concept that the term "recurrent" should be reserved for cases of several RTIs per fall-winter season, e.g., three or more. [5, 11] Several factors such as day care in local nursery and short duration of breastfeeding predispose to recurrent RTIs, particularly otitis media, as well as to wheezy bronchitis, [12] and should therefore be considered as covariates in clinical studies.
In addition to being the most frequent causative agents of respiratory disease, viral infections can predispose to bacterial superinfection. The proportion of children with mixed viral and bacterial RTIs found in studies using serology or antigen detection in serum or urine has been reported to be as high as 40%. However, these methods may be inadequate for assessing the clinical importance of bacterial infection or the need for antimicrobial treatment. [13] In order to provide a more accurate quantitative estimate of the overall treatment effects of a frequently employed immunostimulant, we performed a metaanalysis of studies in children with a history of recurrent RTIs. As in adults, [14] limiting the assessment to the proportion of children without any RTI after treatment with an immunostimulant may provide a biased picture, so the cut-off was therefore set at 3 or more RTIs over 6 months.
Methods
Objective
The primary objective of this meta-analysis was to provide a more accurate estimate of the overall treatment effects of OM-85 BV from a clinical point of view, choosing clinically relevant end points as described in the study by Schaad et al. [11] The cut-off for the outcomes was set at 6 months; the following criteria were defi ned a priori (RTI as defi ned in each study protocol): 1) Primary endpoint: proportion of patients with recurrent RTIs (that is ≥3 RTIs per 6 months);
2) Secondary endpoints: proportion of patients with at least one RTI and mean number of RTIs during 6 months.
No distinction was made between the different clinical diagnoses of RTIs. Since the frequency of RTIs decreases with the age of children and since the number of RTIs in the current season correlates with the number of events in the preceding year, [11, 15] examination of these two variables as a control of comparability of the patient populations at admission to the trial was decided upon. The guidelines provided by the Cochrane Collaboration Handbook for Reviews [16] have been applied in the analysis of the clinical data.
Search strategy
The data sources for the identifi cation of trials included bibliographic databases (TOXLINE, MEDLINE, HealthSTAR, AIDSLINE and CANCERLIT, Embase, AMED, Cochrane Library, PudMed (/www.ncbi.nlm. nih.gov), TOXMAP, TOXLINE Special, DART Special, HSDB, IRIS, ITER, GENETOX, CHEMIDplus, HazMap), hand-searching reference lists from pertinent review articles and books, and personal contacts with experts active in the area and manufacturers up to April 2009. Full disclosure of the product documentation including requested statistical and offi cial reports by the manufacturer in Switzerland warranted a minimal publication bias. All papers were screened, and any dealing with prospective clinical trials were retained for classifi cation according to the selection criteria described below. In case of double publications, the authors retained those which were most recent and/or had been published in a peer-reviewed journal.
All trials eligible were summarized in a tabulated format. The standard table included a full reference, a quality rating, the type of pathology, demographic data and treatments, end-points and adverse events. The trials dealing with pediatric respiratory tract infections were retained.
Material scrutinized
The electronic databases identifi ed recurrent infections, OM-85, Broncho-Vaxom, Imocur, placebo, doubleblind and infants (age, 1-23 months) / children (age, 2-12 years) in 22 publications. Two additional publications of clinical studies were identifi ed through other channels as mentioned above, and duly scrutinized.
Five studies were descriptive, open-labelled pediatric studies and one was a cost-effectiveness model analysis; these had to be discarded. Ten comparative studies were excluded as they did not comply with one or more criteria (Table 1) . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Eight studies were retained as relevant trials dealing with secondary prevention, and were retained for closer examination (Table 2) . [11, [27] [28] [29] [30] [31] [32] [33] Four of these trials were conducted in Western Europe and the remaining four in Mexico: they were all totally or partially industry-sponsored.
Selection criteria
Initially, all articles, published and unpublished trials, were considered for review. They were subsequently OM-85 BV in pediatric respiratory infections
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classifi ed by study design, screened and weighted, based on their methodological quality (methods, participants, interventions, outcome measures and results). Quality assessment was based on a rating of the trials by the criteria published by Jadad et al. [34] Eleven studies were excluded as they were nonblinded or incomplete. Nine studies were retained as relevant trials and, fi nally, eight dealing with secondary prevention were included in the meta-analysis (Table  2) . [11, [27] [28] [29] [30] [31] [32] [33] All trials only admitted children with a documented history of recurrent RTIs.
Regarding similarities and differences in the trials selected, the study of Schaad et al [11] required the patients to actually have an episode of RTI at admission, while all the other studies only admitted children with a documented history of recurrent RTIs. The patients studied by Gomez-Barreto et al [28] had sinusitis, and those reported by Zagar and Löfl erBadzek [33] had chronic rhinosinusitis. The trial of JaraPerez and Berber [30] included only girls living in an orphanage, and the trial of Del-Rio-Navarro et al [27] included children with subnormal serum IgG. JaraPerez and Berber [30] and Schaad et al [32] provided clinical descriptions of the RTIs which are not discussed herein.
The dosing schedules used in the trials included in this meta-analysis are shown in Table 3 .
Statistical analysis
Data were extracted from the pertinent publications and/or study reports in order to obtain for each of the selected trials the key variables defi ned as endpoints and the demographic data deemed of interest as set forth in the trial by Schaad et al [11] (age of the patient and number of RTIs over the preceding 12 months, number of patients completing trial). These data were checked for consistency and adequacy of tests employed. Missing data were reconstructed through iterative procedures. The completed database was entered in Review Manager 2.4.7 software of the Cochrane collaboration; binary data were examined by the Peto-Mantel-Haenszel test. [35] Whenever the authors specifi ed two sets of data, the intent to treat analysis was chosen. The denominator 'N' indicated the number of patients reported by the authors; if not specifi ed, 'N' was the number of patients who were admitted to the trial. Sensitivity analysis was made by sequential elimination of trials and by elimination of outlier trials, with an outlier being defi ned as "an extreme value that 
Results
Key demographic data, comparability at baseline As described in the Methods section, since the age of the children and the number of RTIs in the preceding year are correlated with the number of RTIs to be expected during the trial, these two variables were regarded as a control of comparability of the patient populations at admission to the trial. The mean number of RTIs in the previous year was similar in the two populations (mean of studies with the information: 6.12±3.74 RTIs in the OM-85 BV populations vs. 6.23±3.52 RTIs in the placebo), but no such information was available in the study by Gomez-Barreto [28] while the study by Paupe [31] provided some other relevant information about the similarity between therapeutic groups. With these caveats, the patient population can be accepted as homogeneous.
The number of drop-outs is comparatively small in both therapeutic groups; in the majority of the cases, patients dropped out because of administrative reasons.
In Table 4 the mean ages at admission (pooled mean & SD) and the number of patients are depicted, whereas Table  5 shows the mean number of RTIs in the previous year.
Proportion of patients with RTIs
Although the data were heterogeneous, 32% of the patients within the OM-85 BV treated population had recurrent RTIs (≥3 RTIs per 6 months), vs. 58.2% of the placebo treated population, indicating that the active treatment led to 26.2% fewer patients with recurrent RTIs (Fig. 1) . The large proportion of placebo patients without recurrent RTIs is probably best explained by the natural trend of children to suffer from fewer RTIs as they grow older.
Sensitivity analysis by sequential elimination of trials yielded odds ratios between 0.42 and 0.6, and signifi cance level unchanged at P<0.001. After elimination of the outlier trials by Jara-Perez, [30] which showed the largest difference between treatments, and by Schaad, [32] which tilted towards placebo, the database became homogeneous, showing that there In both treatment groups, the majority of children had at least one RTI during the study period (Table  6 ). Although the data were somewhat heterogeneous, over 16.2% of patients had no RTI in the period under consideration within the OM-85 BV treated population (27.3% with OM-85 BV vs. 11.1% with placebo). Likewise, there was also a signifi cant reduction in the odds ratio (OR OM-85 BV: placebo was 0.33 [95% CI: 0.23, 0.49]). Sensitivity analysis by sequential elimination of trials yielded odds ratios between 0.38 and 0.52, signifi cance level unchanged at P<0.001.
The trials therefore indicated that the population treated with OM-85 BV had signifi cantly and consistently fewer patients with one or more RTIs in a 6-month period (Table 6 ). Moreover, after elimination of the largest favorable "outlier", i.e., the trial of DelRio-Navarro [27] in children with IgG defi ciencies, and the worst trial outcome for this variable, [11] this fi gure was 17.0%, which was even more signifi cant.
Mean number of RTIs in 6 months
The analysis of the mean number of RTIs over 6 months had to be regarded with some caution since the data were actually ordinal (that is, natural whole numbers) and not all trials were suitable for such an analysis because of differences in variances. Nevertheless, the mean number of RTIs was signifi cantly lower in the OM-85 BV treated population, by an average of -1.15 (95% CI: -1.55, -0.75) RTIs/6 months ( Table 7) . After eliminating the outlier studies for this variable (i.e., 
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Gutierrez-Tarango [29] & Schaad [32] ) the mean number of RTIs continued to be signifi cantly lower in the OM-85 BV treated population, by an average of -1.10 (95% CI: -1.64, -0.56) RTIs/6 months.
The weighted mean difference (WMD; also defi ned as "effect size") between mean numbers of RTIs over 6 months was -1.21 [95% CI: -1.39, -1.03] in favor of the active treatment (P<0.00001), although the test for heterogeneity was also highly signifi cant. This heterogeneity was probably due to the differences in age of patients and in the number of RTIs in the preceding year.
Several co-variates were likely to infl uence the outcomes and might explain the heterogeneity found in some variables. They were briefl y illustrated, although they had not been submitted to a formal analysis. The mean number of RTIs was consistent with the number of RTIs in the preceding year and with the age of the patients (Fig. 2) . Namely, the number of RTIs in the preceding year appeared to have a major bearing on the results, the benefi t of OM-85 BV was markedly greater in children with a history of very frequent RTIs (confi rmed by multiple stepwise regression analysis in a subset of trials with raw data available, data not shown). The quality assessment of the studies, i.e., the Jadad rating system, had no evident infl uence on the outcomes. The funnel plots, which should be regarded as a generic instrument for examining small study effects rather than a tool to diagnose specifi c types of bias, did not suggest the existence of publication or any other major bias in this meta-analysis.
Safety
The incidence of minor adverse events in the clinical trials was 17.7% for the OM-85 BV treated and 18.2% for the placebo treated patients; the majority of adverse events were gastrointestinal or cutaneous fi ndings. Serious adverse events were reported in 1% vs. 0.5%, withdrawals due to adverse event in 1.3% vs. 0.7%, respectively. No causal relationship has been established for any of these adverse events. No laboratory abnormalities in relation with OM-85 BV have been reported in the literature. There were neither deaths nor serious adverse events attributed or possibly attributable to the study medication.
Discussion
Steurer-Stey et al [37] used a partially meta-analytical approach of published data with OM-85 BV; their fi ndings, however, remained fragmentary due to failure to request additional information from the manufacturer or other sources. Moreover, their report also analyzed other bacterial immunostimulants. They concluded that their "systematic review provides weak evidence that oral immunostimulation with bacterial extracts prevents acute RTIs in children." There was a trend for fewer infections over 6 months of follow-up in children not in day care as well as a small reduction in number of antibiotic courses.
Our study showed that with the active treatment there were 26.2% fewer patients with recurrent RTIs OM-85 BV in pediatric respiratory infections Systematic review (i.e., ≥3 RTI/6 months). The fact that the population of the different trials included in the meta-analysis is homogeneous (after excluding the two 'outliers') in terms of this variable lends strength to the highly signifi cant results in favor of OM-85 BV.
The proportion of patients with any RTI (i.e., ≥1 RTI/6 months) was reduced by 16.2% in our study, but this variable is of lesser clinical relevance in view of the multiple agents which can cause acute symptoms of an RTI during one single season, probably involving different defence mechanisms. Sensitivity analysis was made for all variables and no particular trial driving the effi cacy outcomes was identifi ed, thus corroborating the results. In line with similar analyses, [38, 39] the mean number of RTIs was reduced by 35.5% but the data, although a highly signifi cant difference was found in favor of OM-85 BV, are very heterogeneous. The heterogeneity in the secondary outcomes is probably explained by clinical and methodological diversity, dependent on the age, the risk of RTIs (as N RTIs in the preceding year) and other variables. For example, the 'outlier' study of Jara-Perez [30] had several particular characteristics as it was conducted under the very controlled conditions of an orphanage for girls.
Exploratory analysis indicates that effi cacy is more pronounced in patients at high risk of recurrent RTIs; the benefi t of OM-85 BV as compared to placebo was notoriously greater in children with a history of very frequent RTIs.
The infl uence of industry-sponsoring on the outcomes of trials has been discussed controversially; that is, no infl uence was found in some cases [40] while in others the results tipped in favor of the sponsored drug. [41] Metaanalysis sponsored by industry came to more "drugfriendly" conclusions than independent studies, even if the estimated treatment effect was similar. [42] The positive and negative predictive value of metaanalysis should be taken into consideration. Agreement between meta-analyses and large clinical trials of therapeutic interventions can be expected in 68% of the cases, while a statistically signifi cant difference was found in only 12% of the cases; in no case, however, there was a divergence in which the randomized clinical trial and the meta-analysis yielded statistically signifi cant and opposite results. [43] It is important to note that the outcomes concerning the primary variable were homogeneous in robust analysis since heterogeneity in the outcomes of individual trials appears to be an important predictor of discrepancy between metaanalyses and large clinical trials. [44] We believe that this analysis may help both the practitioner in identifying the best candidates for this immunostimulant therapy and the investigators in setting up new randomized controlled trials in this complex fi eld. Future studies should provide details of the RTIs occurring during the observation period employing a standardized clinical classifi cation.
